Cytomegalovirus antibody status of donor/recipient does not influence the incidence of bronchiolitis obliterans syndrome in lung transplantation

Journal of Heart and Lung Transplantation

Volumn 22, Issue 3, 2003, Pages 287-291

  Luckraz, Heyman ^a   Sharples, Linda ^b   McNeil, Keith ^a   Wreghitt, Tim ^c   Wallwork, John ^a  

^a PAPWORTH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS ANTIBODY;

ARTICLE; BRONCHIOLITIS; CONTROLLED STUDY; CYTOMEGALOVIRUS; DATA BASE; DISEASE PREDISPOSITION; DONOR; HUMAN; LUNG TRANSPLANTATION; PATIENT CARE; PRIORITY JOURNAL; RECIPIENT; RETROSPECTIVE STUDY; RISK FACTOR;

ANTIBODIES, VIRAL; BRONCHIOLITIS OBLITERANS; CYTOMEGALOVIRUS INFECTIONS; GRAFT REJECTION; HEART-LUNG TRANSPLANTATION; HUMANS; INCIDENCE; LUNG TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TISSUE DONORS;

EID: 0037334097     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-2498(02)00471-0     Document Type: Article

References (20)

1. Fields BN, Knipe DM, Howey PM. In: Fields virology. Volume 2, 3rd ed. Philadelphia: Lippincott-Raven, 1996.
2. Heng D., Sharples L.D., McNeil K., Stewart S., Wreghitt T., Wallwork J. Bronchiolitis obliterans syndrome incidence, natural history, prognosis, and risk factors . J Heart Lung Transplant. 17:1998;1255-1263.
3. Girgis R.E., Tu I., Berry G.J., et al. Risk factors for the development of obliterative bronchiolitis after lung transplantation. J Heart Lung Transplant. 15:1996;1200-1208.
4. Paradis I. Bronchiolitis obliterans pathogenesis, prevention, and management . Am J Med Sci. 315:1998;161-178.
5. The Registry of the International Society for Heart and Lung Transplantation. ISHLT 18th annual report, 2001.
6. Bando K., Paradis I.L., Similo S., et al. Obliterative bronchiolitis after lung and heart-lung transplantation An analysis of risk factors and management . J Thorac Cardiovasc Surg. 110:1995;4-13.
7. Cooper J.D., Billingham M., Egan T., et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. J Heart Lung Transplant. 12:1993;713-716.
8. Perreas K, Milano C, Buchan K, et al. CMV prophylaxis and ganciclovir. Abstract presented at ISHLT 2000 meeting, Osaka, Japan
9. Yousem S.A., Berry G.J., Cagle P.T., et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection lung rejection study group . J Heart Lung Transplant. 15:1996;1-15.
10. Duncan S.R., Valentine V., Roglic M., et al. T-cell receptor biases and clonal proliferations among lung transplant recipients with obliterative bronchiolitis. J Clin Invest. 97:1996;2642-2650.
11. Theise N.D., Haber M.M., Grimes M.M. Detection of cytomegalovirus in lung allografts Comparison of histologic and immunohistochemical findings . Am J Clin Pathol. 96:1991;762-766.
12. Smith M.A., Sundaresan S., Mohanakumar T., et al. Effect of development of antibodies to HLA and cytomegalovirus mismatch on lung transplantation survival and development of bronchiolitis obliterans syndrome. J Thorac Cardiovasc Surg. 116:1998;812-820.
13. Luckraz H, Parameshwar J, Wreghitt T, Wallwork J, Large SR. Does CMV status influence acute and chronic rejection in heart transplantation during the ganciclovir era? Abstract presented at the ISHLT meeting 2002, Washington, DC. J Heart Lung Transplant 2002;21:111-2.
14. Taylor P.M., Rose M.L., Yacoub M.H. Expression of MHC antigens in normal human lungs and transplanted antigens with obliterative bronchiolitis. Transplantation. 48:1989;506-510.
15. You X.M., Steinmuller C., Wagner T.O., Bruggeman C.A., Haverich A., Steinhoff G. Enhancement of cytomegalovirus infection and acute rejection after allogeneic lung transplantation in the rat virus-induced expression of major histocompatibility complex class II antigens . J Heart Lung Transplant. 15:1996;1108-1119.
16. Beck S., Barrell B.G. Human cytomegalovirus encodes a glycoprotein homologous to MHC class-I antigens. Nature. 331:1988;269-272.
17. Arbustini E., Morbini P., Grasso M., et al. Human cytomegalovirus early infection, acute rejection and major histocompatibility class II expression in transplanted lung. Transplantation. 61:1996;418-427.
18. Geist L.J., Hopkins H.A., Dal L.Y., He B., Monick M.M., Hunninghake G.W. Cytomegalovirus modulates transcription factors necessary for the activation of the tumor necrosis factor-alpha promoter. Am J Resp Cell Mol Biol. 16:1997;31-37.
19. Carney W.P., Rubin R.H., Hoffman R.A., Hansen W.P., Healey K., Hirsch M.S. Analysis of T lymphocyte subsets in cytomegalovirus mononucleosis. J Immunol. 126:1981;2114-2116.
20. van den Berg A.P., Meyaard L., Otto S.A., et al. Cytomegalovirus infection associated with a decreased proliferative capacity and increased rate of apoptosis of peripheral blood lymphocytes. Transplant Proc. 27:1995;936-938.